Hikma Pharmaceuticals Regulatory News (HIK)

12 May 2009 17:37



Annual Information Update

LONDON, 12 May 2009. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company")(LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the previous 12 months. The information referred to in this Update was up to date at the time the information was published, but some information may now be out of date.

Stock Exchange announcements

Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (www.londonstockexchange.com/marketnews) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/).The Stock Exchange announcements made during the defined period are:

All of the above announcements were also made by the Company via the NasdaqDubai stock exchange CANDI system. These announcements may be viewed and downloaded from the NasdaqDubai website (www.candi.nasdaq.com).

Documents filed with the Financial Services Authority

The company has filed the following documents with the Financial Services Authority ("FSA") over the previous 12 months. These documents are available to be viewed via the UKLA's Document Viewing Facility at the Financial Services Authority, 25 the North Colonnade, London, E14 5HS or at the Company's registered office.

Documents Filed with the Document Viewing Facility

Documents filed with Companies House

The Company submitted filings to Companies House in relation to the Company's annual return, financial report & accounts, allotments of shares, Articles of Association, and ordinary and special resolutions passed at the company's 2008 Annual General Meeting. Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House Direct at www.direct.companieshouse.gov.uk. 

Copies of all documents can be obtained from the Company at the registered office, 13 Hanover Square, London, W1S 1HW. 

Henry Knowles Company Secretary12 May 2009

- ENDS -

Enquiries:

Notes to Editors

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2008, the Group achieved revenues of $580.7 million (2007 $449 million) and profit attributable to shareholders was $57.1 million (2007 $63 million). For news and other information, please visit www.hikma.com.